Chronic lymphocytic leukemia (Cll) biomarkers
A technology of biomarkers and drugs, applied in the fields of biomaterial analysis, biochemical equipment and methods, microbial determination/inspection, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment
[0246] Biomarkers to predict CLL response to CD20 antibody Materials and methods
[0247] sample:
[0248] Analysis of pretreatment patient samples from an international, multicenter, open-label phase III trial randomizing CLL patients to receive R-FC (rituximab plus fludarabine / cyclophosphamide) Or FC alone (fludarabine / cyclophosphamide). The main objective was to demonstrate better progression-free survival (PFS) of R-FC compared to FC alone. The study protocol was approved by the Institutional Review Board at the participating centers and all patients gave informed consent. Details of the trial design and eligibility criteria are described in Robak et al. J. Clin. Oncol. 28(10):1756-1765 (2010). Patients were selected for molecular genetic analysis of peripheral blood samples based on RNA availability and signed informed consent.
[0249] Pre-treatment peripheral blood mononuclear cell (PBMC) samples positively selected for CD19+ cells were available from n=301 patien...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 